Common Contracts

13 similar Exclusive Agency Agreement contracts by BIT Mining LTD, Oncternal Therapeutics, Inc., Aeterna Zentaris Inc., others

BIT Mining Limited Units 813&815, Level 8, Core F, Cyberport 3
Exclusive Agency Agreement • August 18th, 2022 • BIT Mining LTD • Services-computer processing & data preparation • New York
BIT Mining Limited Units 813&815, Level 8, Core F, Cyberport 3
Exclusive Agency Agreement • June 27th, 2022 • BIT Mining LTD • Services-computer processing & data preparation • New York
STRICTLY CONFIDENTIAL Kintara Therapeutics, Inc. 12707 High Bluff Dr., Suite 200 San Diego, CA 92130 Attn: Saiid Zarrabian, Chief Executive Officer Dear Mr. Zarrabian:
Exclusive Agency Agreement • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between Kintara Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwrig

STRICTLY CONFIDENTIAL Xenetic Biosciences, Inc.
Exclusive Agency Agreement • July 28th, 2021 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Anavex Life Sciences Corp.
Exclusive Agency Agreement • June 24th, 2021 • Anavex Life Sciences Corp. • Services-commercial physical & biological research • New York
STRICTLY CONFIDENTIAL Enochian BioSciences, Inc. Century City Medical Plaza
Exclusive Agency Agreement • June 16th, 2021 • Enochian Biosciences Inc • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Oncternal Therapeutics, Inc. 12230 El Camino Real Suite 300 San Diego, California 92130 Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive Officer
Exclusive Agency Agreement • March 12th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between Oncternal Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwr

STRICTLY CONFIDENTIAL Oncternal Therapeutics, Inc. 12230 El Camino Real Suite 300 San Diego, California 92130 Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive Officer
Exclusive Agency Agreement • March 11th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between Oncternal Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwr

STRICTLY CONFIDENTIAL Arcadia Biosciences, Inc.
Exclusive Agency Agreement • December 22nd, 2020 • Arcadia Biosciences, Inc. • Agricultural production-crops • New York
STRICTLY CONFIDENTIAL Ra Medical Systems, Inc.
Exclusive Agency Agreement • May 15th, 2020 • Ra Medical Systems, Inc. • Surgical & medical instruments & apparatus • New York
Cocrystal Pharma, Inc. 19805 N. Creek Parkway Bothell, WA 98011 Attn: Gary Wilcox, Chief Executive Officer Dear Mr. Wilcox:
Exclusive Agency Agreement • March 4th, 2020 • Cocrystal Pharma, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between Cocrystal Pharma, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright i

STRICTLY CONFIDENTIAL Aeterna Zentaris Inc.
Exclusive Agency Agreement • February 21st, 2020 • Aeterna Zentaris Inc. • Pharmaceutical preparations • New York
October 14, 2016
Exclusive Agency Agreement • November 10th, 2016 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations • New York